NCT07266779已完成1 期
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets of Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in Healthy, Adult, Human Subjects Under Fed Condition.
Humanis Saglık Anonim Sirketi1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年8月22日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration Cmax
研究概览
简要总结
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of test product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg film coated tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Reference product (R) of Segluromet 7.5 mg/ 1000 mg film coated tablets of Merck Sharp & Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands, in Healthy, adult, human Subjects Under fed Condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject will be selected for study participation, if they meet the following criteria:
- •Subjects aged between 18 to 45 years (both inclusive).
- •Subjects' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
- •Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- •Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
- •Subjects having clinically acceptable chest X-Ray (PA view), if taken.
- •Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
- •Subjects having negative urine alcohol test / breath alcohol test.
- •Non-smoker.
- •Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- •Subject with Creatinine Clearance ˃45 ml/min.
- •For male Subjects:
- •Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period
- •For Female Subjects:
- •Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
- •Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- •Subjects having negative urine pregnancy test at screening and negative serum β-hCG pregnancy test on admission day of period 01 (only for female subjects).
排除标准
- •Subjects will be excluded from the study, if they meet any of the following criteria:
- •Hypersensitivity to Ertugliflozin and Metformin or related class of drugs or any of its excipients or heparin.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period
- •Presence of alcoholism or drug abuse.
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer or basal or squamous cell carcinoma.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids dosage form like tablets or capsules.
- •Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period
- •Major illness within past 3 months.
- •Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- •Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period
- •Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
- •Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- •History of any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis).
- •History of Diabetic pre-coma.
- •History of acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock.
- •History of disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, shock.
- •History of Hepatic impairment or acute alcohol intoxication.
- •Female subjects who are currently breast feeding.
研究组 & 干预措施
Ertugliflozin/Metformin film coated tablets
Experimental
7.5 mg Ertugliflozin / 1000 mg Metformin
干预措施: Ertugliflozin/Metformin film coated tablets (Drug)
Ertugliflozin/Metformin film coated tablets
Experimental
7.5 mg Ertugliflozin / 1000 mg Metformin
干预措施: Segluromet film coated tablets (Drug)
Segluromet film coated tablets
Active Comparator
7.5 mg Ertugliflozin / 1000 mg Metformin
干预措施: Ertugliflozin/Metformin film coated tablets (Drug)
Segluromet film coated tablets
Active Comparator
7.5 mg Ertugliflozin / 1000 mg Metformin
干预措施: Segluromet film coated tablets (Drug)
结局指标
主要结局
Peak Plasma Concentration Cmax
时间窗: 72 hours
Acceptance range for bioequivalence is 80.00%-125.00% for geometric least square mean ratio (T/R) and it's 90% confidence interval for Cmax
Area Under the Curve from time zero to time of last measurable concentration AUC0-t
时间窗: 72 hours
Acceptance range for bioequivalence is 80.00%-125.00% for geometric least square mean ratio (T/R) and it's 90% confidence interval for AUC0-t.
次要结局
- Area Under the Curve from time zero to time infinite AUC0-∞(72 hours)
- Time to reach peak plasma concentration Tmax(72 hours)
- Plasma Elimination Half-Life t1/2(72 hours)
- The elimination rate constant associated with the terminal (log-linear) portion of the curve Kel(72 hours)
- AUC0-t/ AUC0-∞(72 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated TabletsNCT06932159Humanis Saglık Anonim Sirketi40
已完成
1 期
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult SubjectsHealthy SubjectsHuman VolunteersHealthy ParticipantsBioequivalenceNCT05519514Abbott56
已完成
1 期
Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg)Chronic Heart FailureNCT06922253Humanis Saglık Anonim Sirketi48
已完成
1 期
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed ConditionsHealthyNCT01045434Dr. Reddy's Laboratories Limited62
已完成
1 期
To Compare and Evaluate the Oral Bioavailability of Bilastine 20 mg Orally Dispersible Tablet With That of Bilaxten (Bilastine) 20 mg Orally Dispersible Tablet in Healthy, Adult, Human Subjects Under Fasting ConditionsUrticariaNCT07042828Humanis Saglık Anonim Sirketi42